Clinical trial
Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous…
NCT00114101 · National Cancer Institute (NCI), NIH · Active, not recruiting
Key facts
| NCT number | NCT00114101 |
|---|---|
| Title | Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant |
| Official title | A Phase III Randomized, Double-Blind Study of Maintenance Therapy With CC-5013 (NSC # 703813) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma, Refractory Multiple Myeloma, Smoldering Multiple Myeloma |
| Intervention type | Drug, Other, Procedure |
| Interventions | Autologous Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Lenalidomide, Melphalan, Peripheral Blood Stem Cell Transplantation, Placebo Administration |
| Enrollment | 460 |
| Start date | Dec 15, 2004 |
| Primary completion | Dec 31, 2012 |
| Completion | Feb 22, 2026 |
| First posted | Jun 14, 2005 |
| Last update posted | Nov 24, 2025 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: